Literature DB >> 18586925

Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: present status and future prospects.

Jan P van Meerbeeck1, Sabine Meersschout, Rebecca De Pauw, Indira Madani, Wilfried De Neve.   

Abstract

Locally advanced stages account for approximately one third of the incident presentations of non-small cell lung cancer (NSCLC). Optimal treatment in selected patients consists of an integration of chemotherapy and radiation therapy. Both modalities have seen numerous advances in the last decade. This article reviews the current status and outcome of treatment in stage III NSCLC, with special emphasis on the role of novel techniques in radiation treatment, including intensity-modulated radiation therapy. The obstacles for improving local control are identified and the technical progress that aims at removing these obstacles is addressed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586925     DOI: 10.1634/theoncologist.2007-0196

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  8 in total

1.  Differential effect of soy isoflavones in enhancing high intensity radiotherapy and protecting lung tissue in a pre-clinical model of lung carcinoma.

Authors:  Gilda G Hillman; Vinita Singh-Gupta; David J Hoogstra; Lisa Abernathy; Joseph Rakowski; Christopher K Yunker; Shoshana E Rothstein; Fazlul H Sarkar; Shirish Gadgeel; Andre A Konski; Fulvio Lonardo; Michael C Joiner
Journal:  Radiother Oncol       Date:  2013-09-07       Impact factor: 6.280

2.  From bench to bedside: the growing use of translational research in cancer medicine.

Authors:  Erin M Goldblatt; Wen-Hwa Lee
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

3.  Soy Isoflavones Promote Radioprotection of Normal Lung Tissue by Inhibition of Radiation-Induced Activation of Macrophages and Neutrophils.

Authors:  Lisa M Abernathy; Matthew D Fountain; Shoshana E Rothstein; John M David; Christopher K Yunker; Joseph Rakowski; Fulvio Lonardo; Michael C Joiner; Gilda G Hillman
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609

Review 4.  Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer.

Authors:  Nicholas Thatcher; Jim Heighway
Journal:  Oncologist       Date:  2010-10-07

5.  Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.

Authors:  Gilda G Hillman; Fulvio Lonardo; David J Hoogstra; Joseph Rakowski; Christopher K Yunker; Michael C Joiner; Gregory Dyson; Shirish Gadgeel; Vinita Singh-Gupta
Journal:  Transl Oncol       Date:  2014-05-23       Impact factor: 4.243

6.  Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial.

Authors:  Xiao-Cang Ren; Quan-Yu Wang; Rui Zhang; Xue-Ji Chen; Na Wang; Yue-E Liu; Jie Zong; Zhi-Jun Guo; Dong-Ying Wang; Qiang Lin
Journal:  BMC Cancer       Date:  2016-04-23       Impact factor: 4.430

7.  Innate Immune Pathways Associated with Lung Radioprotection by Soy Isoflavones.

Authors:  Lisa M Abernathy; Matthew D Fountain; Michael C Joiner; Gilda G Hillman
Journal:  Front Oncol       Date:  2017-01-23       Impact factor: 6.244

8.  Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.

Authors:  Martina Vrankar; Izidor Kern; Karmen Stanic
Journal:  Radiat Oncol       Date:  2020-10-29       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.